<DOC>
	<DOCNO>NCT02234011</DOCNO>
	<brief_summary>This study do learn whether administration intranasal ( inhaled nose ) ketamine reduces symptoms obsessive-compulsive disorder ( OCD ) . Ketamine approve U.S. Food Drug Administration ( FDA ) anesthetic agent ( medicine reduce pain surgery procedure ) ketamine approve FDA treatment OCD . The investigator believe ketamine may effective reduce symptom OCD due ability decrease activity specific brain chemical call glutamate . Previous study show people OCD abnormal level glutamate brain . This first time intranasal ketamine studied people OCD . However , study do past use intravenous ( IV ; needle vein arm ) ketamine people OCD , intranasal ketamine study people psychiatric condition . This research study compare ketamine placebo . The placebo look exactly like ketamine , contain ketamine . At time study , investigator give ketamine . At another time , investigator give placebo . Placebos use research study see result due study drug due reason .</brief_summary>
	<brief_title>A Trial Intranasal Ketamine Treatment Obsessive-Compulsive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>1 . Male female age ≥ 18 ≤ 55 2 . Meets DSMIV50 criterion OCD primary present diagnosis determine investigator ( participant secondary comorbid dysthymia , major depression , anxiety disorder , eat disorder , obsessivecompulsive spectrum disorder still eligible enrollment ) . 3 . Score ≥ 18 YBOCS screen 1 . Unwillingness inability provide write informed consent . 2 . Active suicidal ideation screen 3 . Lifetime history psychotic disorder autism spectrum disorder 4 . DSMIV diagnosis alcohol substance dependence , exception nicotine dependence , within three month prior screen 5 . Any history intolerance hypersensitivity ketamine 6 . Any history nasal/sinus anomaly dysfunction ( e.g. , nasal obstruction history nasal surgery ) 7 . Clinically significant medical disease include , limited , cardiac ( include uncontrolled hypertension uncontrolled hypotension , arrhythmia , congestive heart failure , angina ) , pulmonary , hepatic , renal , endocrine disorder , would increase risk participant interfere interpretation result judge principal investigator . 8 . Clinically significant neurologic disease include , limited , seizure disorder , neurodegenerative disease , transient ischemic attack , neural vascular disease , stroke , cerebral aneurysm , history traumatic brain injury . 9 . Female participant positive serum urine pregnancy test screen 10 . Pregnancy . Females childbearing potential must use effective contraceptive method ( e.g. , abstinence , prescription oral contraceptive , contraceptive injection , doublebarrier method , male partner sterilization ) . Women childbearing potential define : postmenopausal ( &gt; 45 year age amenorrhea least 12 month , age menorrhea least 6 month serum follicle stimulate hormone ( FSH ) level &gt; 40 IU/ml ) ; permanently sterilize ( e.g. , tubal occlusion , hysterectomy , bilateral salpingectomy ) ; otherwise incapable pregnancy . 11 . Female participant lactate . 12 . Any screening laboratory abnormality deem clinically significant investigator 13 . Currently take opiate pain medication , dextromethorphan , St. John 's Wort , theophylline , tramadol . 14 . Any participation investigational drug trial within 30 day enrollment study . 15 . Contraindication MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>